patent infringement

zynga-owes-ibm-$45m-after-using-1980s-patented-technology-for-hit-games

Zynga owes IBM $45M after using 1980s patented technology for hit games

A bountiful harvest awaits —

Zynga plans to appeal and confirms no games will be affected.

Zynga owes IBM $45M after using 1980s patented technology for hit games

Zynga must pay IBM nearly $45 million in damages after a jury ruled that popular games in its FarmVille series, as well as individual hits like Harry Potter: Puzzles and Spells, infringed on two early IBM patents.

In an SEC filing, Zynga reassured investors that “the patents at issue have expired and Zynga will not have to modify or stop operating any of the games at issue” as a result of the loss. But the substantial damages owed will likely have financial implications for Zynga parent company Take-Two Interactive Software, analysts said, unless Zynga is successful in its plans to overturn the verdict.

A Take-Two spokesperson told Ars: “We are disappointed in the verdict; however, believe we will prevail on appeal.”

For IBM, the win comes after a decade of failed attempts to stop what it claimed was Zynga’s willful infringement of its patents.

In court filings, IBM told the court that it first alerted Zynga to alleged infringement in 2014, detailing how its games leveraged patented technology from the 1980s that came about when IBM launched Prodigy.

But rather than negotiate with IBM, like tech giants Amazon, Apple, Google, and Facebook have, Zynga allegedly dodged accountability, delaying negotiations and making excuses to postpone meetings for years. In that time, IBM alleged that rather than end its infringement or license IBM’s technologies, Zynga “expanded its infringing activity” after “openly” admitting to IBM that “litigation would be the only remaining path” to end it.

This left IBM “no choice but to seek judicial assistance,” IBM told the court.

IBM argued that its patent, initially used to launch Prodigy, remains “fundamental to the efficient communication of Internet content.” Known as patent ‘849, that patent introduced “novel methods for presenting applications and advertisements in an interactive service that would take advantage of the computing power of each user’s personal computer (PC) and thereby reduce demand on host servers, such as those used by Prodigy,” which made it “more efficient than conventional systems.”

According to IBM’s complaint, “By harnessing the processing and storage capabilities of the user’s PC, applications could then be composed on the fly from objects stored locally on the PC, reducing reliance on Prodigy’s server and network resources.”

The jury found that Zynga infringed that patent, as well as a ‘719 patent designed to “improve the performance” of Internet apps by “reducing network communication delays.” That patent describes technology that improves an app’s performance by “reducing the number of required interactions between client and server,” IBM’s complaint said, and also makes it easier to develop and update apps.

The company told the court that licensing these early technologies helps sustain the company’s innovations today.

As of 2022, IBM confirmed that it has spent “billions of dollars on research and development” and that the company vigilantly protects those investments when it discovers newcomers like Zynga seemingly seeking to avoid those steep R&D costs by leveraging IBM innovations to fuel billions of dollars in revenue without paying IBM licensing fees.

“IBM’s technology is a key driver of Zynga’s success,” IBM argued back in 2022, and on Friday, the jury agreed.

“IBM is pleased with the jury verdict that recognizes Zynga’s infringement of IBM’s patents,” IBM’s spokesperson told Ars.

Cost of pre-Internet IBM licenses

In its defense, Zynga tried and failed to argue that the patents were invalid, including contesting the validity of the 1980s patent—which Zynga claimed never should have been issued, alleging it was due to “intent to deceive” the patent office by withholding information.

It’s currently unclear what licensing deal IBM offered to Zynga initially or how much Zynga could have paid to avoid damages awarded this week. IBM did not respond to Ars’ request to further detail terms of the failed deal.

But the 1980s patent in particular has been at the center of several lawsuits that IBM has raised to protect its early intellectual property from alleged exploitation by Internet companies. Back in 2006, when IBM sued Amazon, IBM executive John Kelly vowed to protect the company’s patents “through every means available.” IBM followed through on that promise throughout the 2010s, securing notable settlements from various companies, like Priceline and Twitter, where terms of the subsequent licensing deals were not disclosed.

However, IBM’s aggressive defense of its pre-Internet patents hasn’t dinged every Internet company. When Chewy pushed back on IBM’s patent infringement claims in 2021, the pet supplier managed to beat IBM’s claims by proving in 2022 that its platform was non-infringing, Reuters reported.

Through that lawsuit, the public got a rare look into how IBM values its patents, attempting to get Chewy to agree to pay $36 million to license its technologies before suing to demand at least $83 million in damages for alleged infringement. In the end, Chewy was right to refuse to license the tech just to avoid a court battle.

Now that some of IBM’s early patents have become invalid, IBM’s patent-licensing machine may start slowing down.

For Zynga, the cost of fighting IBM so far has not restricted access to its games or forced Zynga to redesign its platforms to be non-infringing, which were remedies sought in IBM’s initial prayer for relief in the lawsuit. But overturning the jury’s verdict to avoid paying millions in damages may be a harder hurdle to clear, as a jury has rejected what may be Zynga’s best defense, and the jury’s notes and unredacted verdict remain sealed.

According to Take-Two’s SEC filing, the jury got it wrong, and Take-Two plans to prove it: “Zynga believes this result is not supported by the facts and the law and intends to seek to overturn the verdict and reduce or eliminate the damages award through post-trial motions and appeal.”

Zynga owes IBM $45M after using 1980s patented technology for hit games Read More »

apple-watch-no-longer-sold-with-blood-oxygen-monitoring-after-patent-battle-loss

Apple Watch no longer sold with blood oxygen monitoring after patent battle loss

Apple Watch Ultra 2

Enlarge / The Apple Watch Ultra 2.

Apple

Starting today, if you buy an Apple Watch Series 9 or Watch Ultra 2 it won’t be able to tell you your blood oxygen levels, a feature that Apple heavily touted when first introducing the capability in 2020. Although the watches will be less capable than watches of the same model sold before today, Apple is selling the pared-down watches at the same prices as before.

On Wednesday, the US Court of Appeals for the Federal Circuit denied [PDF] Apple’s request that an import ban on the smartwatches be lifted for the duration of Apple’s appeal of the ruling that blocked the watches. Apple expects its appeal to take at least a year to be resolved.

In its ruling, the court said:

Our determination is governed by four factors: (1) whether the movant has made a strong showing of likelihood of success on the merits; (2) whether the movant will be irreparably harmed absent a stay; (3) whether issuance of the stay will substantially injure the other parties interested in the proceeding; and (4) where the public interest lies.

In January 2023, the US International Trade Commission (ITC) ruled that Apple Watches infringe two patents for light-based pulse oximetry functionality and components owned by California-headquartered Masimo.

After US President Joe Biden declined to veto the ruling, Apple filed an appeal and pulled the watches on December 21. The company received a temporary stay that enabled it to sell the watches with the questioned capabilities from December 27 until 5 pm ET yesterday. But yesterday’s ruling resulted in the stay being lifted, forcing Apple to either stop selling the watches or to continue selling them but with the disputed feature removed.

When reached for comment, an Apple spokesperson told Ars Technica:

Pending the appeal, Apple is taking steps to comply with the ruling while ensuring customers have access to Apple Watch with limited disruption. These steps include introducing a version of Apple Watch Series 9 and Apple Watch Ultra 2 in the United States without the Blood Oxygen feature. There is no impact to Apple Watch units previously purchased that include the Blood Oxygen feature.

In a statement shared by Bloomberg today, Masimo CEO Joe Kiani said that Wednesday’s decision “affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.”

Same watches, different abilities

Starting today, Apple will only sell the Watch Series 9 and Ultra 2, which both came out in September, with a US Customs and Border Protection-approved software workaround that disables blood oxygen monitoring capabilities. These watches will be available at Apple’s physical and online stores, Apple said. They also have part numbers ending in “LW/A,” per updated Apple support materials.

Users of newly purchased Series 9 and Ultra 2 smartwatches will still have a blood oxygen icon on their watch, but upon tapping the icon, the watch will say, “The Blood Oxygen app is no longer available. Learn more in the Health app on your iPhone.” Once they go to the Health app, users can access a support article on Apple’s website explaining the situation.

Apple’s general product page for the Apple Watch and its websites for the Series 9 and Ultra 2 now include tiny footnotes at the bottom, noting that its watches no longer have the blood oxygen monitoring capabilities that they were announced with. When asked why the watches aren’t less expensive without pulse oximeter functionality, Apple’s rep said that pricing isn’t based on a single feature. It’s worth noting that the watches haven’t become cheaper to make, as they still have the same components as before.

Since the US ITC’s ruling only affects the US, Apple will continue selling the Watch Series 9 and Ultra 2 with blood oxygen monitoring capabilities outside the US.

Apple didn’t respond to Ars’ questions asking if it will redesign its watches so that they can offer blood oxygen monitoring without infringing on any patents. On Tuesday, Bloomberg reported that Apple has “been working on a software update that changes the blood-oxygen app and its algorithms in a way that might circumvent” patent infringement but keep the feature.

Apple Watch no longer sold with blood oxygen monitoring after patent battle loss Read More »

apple-watch-redesigned-without-blood-oxygen-monitoring-to-avoid-import-ban

Apple Watch redesigned without blood oxygen monitoring to avoid import ban

Masimo patent battle —

Apple preps update should patent-infringing Watch Series 9, Ultra 2 be banned again.

Apple Watch Series 9

Enlarge / The Apple Watch Series 9.

Apple

Apple has developed a backup plan for if the Apple Watch Series 9 and Ultra 2 are import banned again. As it currently appeals the US International Trade Commission’s (ITC’s) ruling that its watches violate a patent owned by Masimo, Apple has come up with a software workaround that strips its current smartwatches of their controversial blood oxygen monitoring capabilities.

In January 2023, the ITC ruled that the Watch violated one of California-headquartered Masimo’s light-based pulse oximetry patents. The Apple Watch Series 6, which came out in 2020, was the first Apple smartwatch to use a pulse oximeter sensor.

Facing a US import ban of the current Watch Series 9 and Watch Ultra 2, both released in September 2023, Apple started pulling the smartwatches on December 21. But on December 27, Apple, which filed its appeal against the ITC’s ruling on December 26 (after US President Joe Biden declined to overrule the ITC ruling), received an emergency interim stay from the US Court of Appeals for the Federal Circuit, allowing it to continue selling the Watch.

On Monday, Masimo sent a letter [PDF] to the US Court of Appeals for the Federal Circuit, as spotted by 9to5Mac, stating that US Customs and Border Protection decided on January 12 that Apple has redesigned the Watches so that they do not contain pulse oximetry functionality.

Apple accomplished this through a “software workaround” for smartwatches recently shipped to its physical stores, according to a Bloomberg report from Mark Gurman on Monday. However, the stores will not sell the redesigned watches until Apple headquarters tells them to, Bloomberg reported.

The publication noted that Apple will probably only release the Watches that can’t monitor blood oxygen levels if the US Court of Appeals for the Federal Circuit denies Apple’s request that its stay be upheld for the duration of its appeal against the ITC ruling, which Apple expects to be at least a year, an Apple spokesperson told Ars Technica. Apple expects that ruling to come as early as today.

Currently, the Watch Series 9 and Watch Ultra 2 are still available with blood oxygen monitoring, an Apple spokesperson confirmed to Ars. But Apple hasn’t confirmed how long that will be the case, jeopardizing demand and the perceived value for Apple’s latest smartwatches.

Longer term, Bloomberg also reported that Apple is developing a software update that alters the watches’ blood oxygen monitoring app and algorithms so that users can still check out their blood oxygen but without Apple infringing on any patents.

For the ITC’s part, it responded to Apple’s requests for an extended stay on the import ban in a court filing on January 10 [PDF]. It stated that Apple has provided “a weak and unconvincing case” and that the tech giant’s arguments “amount to little more than an indisputably adjudicated infringer requesting permission to continue infringing the asserted patents.”

Prospective owners of the Apple Watch who value blood oxygen monitoring should keep an eye open for the appeals court’s ruling because it could swiftly result in Apple Watches that they’re considering buying missing a key feature.

Apple Watch redesigned without blood oxygen monitoring to avoid import ban Read More »